IGG4-RD

Clinical trials for IGG4-RD explained in plain language.

Never miss a new study

Get alerted when new IGG4-RD trials appear

Sign up with your email to follow new studies for IGG4-RD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Experimental drug for rare inflammatory disease shows early promise but trial cut short

Disease control Terminated

This study tested elotuzumab, a drug used for multiple myeloma, in people with active IgG4-related disease (IgG4-RD), a rare condition causing inflammation and organ damage. The trial was small (only 8 participants) and was terminated early, so it is unclear if the drug is safe o…

Matched conditions: IGG4-RD

Phase: PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control

Last updated Jun 27, 2026 09:03 UTC

IGG4-RD

Get alerted when new IGG4-RD trials appear

Experimental drug for rare inflammatory disease shows early promise but trial cut short